adenine has been researched along with Leukocytopenia in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-eight patients with advanced breast cancer refractory to prior hormone and/or first-line chemotherapy (with or without anthracycline drugs) were treated with the investigational agent amonafide at a dose of 800 mg/m2 intravenously over 3 hours repeated every 4 weeks." | 9.07 | Phase II study of amonafide in advanced breast cancer. ( Depisch, D; Dittrich, C; Gisslinger, H; Haider, K; Kornek, G; Linkesch, W; Scheithauer, W, 1991) |
| " For illustration, a pharmacodynamic model for leukopenia was constructed by stepwise linear regression from data of 41 patients with cancer treated with the drug amonafide." | 5.07 | Bootstrap validation of pharmacodynamic models defined via stepwise linear regression. ( Mick, R; Ratain, MJ, 1994) |
| "Twenty-eight patients with advanced breast cancer refractory to prior hormone and/or first-line chemotherapy (with or without anthracycline drugs) were treated with the investigational agent amonafide at a dose of 800 mg/m2 intravenously over 3 hours repeated every 4 weeks." | 5.07 | Phase II study of amonafide in advanced breast cancer. ( Depisch, D; Dittrich, C; Gisslinger, H; Haider, K; Kornek, G; Linkesch, W; Scheithauer, W, 1991) |
| "To determine if variability in toxicity of amonafide during phase II trials could be correlated with pharmacokinetic variability." | 2.68 | Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. ( Allen, SL; Costanza, M; Henderson, IC; Ratain, MJ; Rosner, G; Schilsky, RL; Van Echo, DA, 1995) |
| " The goal of this study was to construct and validate a pharmacodynamic model-based dosing strategy for amonafide, to try to further decrease inter-patient variability in leukopenia." | 1.29 | Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. ( Berezin, F; Janisch, L; Kut, M; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 9 (69.23) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| YANASE, T | 1 |
| KASAI, A | 1 |
| YAMANAKA, J | 1 |
| OWAN, T | 1 |
| Ratain, MJ | 4 |
| Rosner, G | 1 |
| Allen, SL | 1 |
| Costanza, M | 1 |
| Van Echo, DA | 1 |
| Henderson, IC | 1 |
| Schilsky, RL | 3 |
| Mick, R | 3 |
| Xiwen, B | 1 |
| Lixin, Y | 1 |
| Junjie, M | 1 |
| Janisch, L | 2 |
| Berezin, F | 2 |
| Vogelzang, NJ | 1 |
| Kut, M | 1 |
| Asbury, R | 1 |
| Blessing, JA | 1 |
| Podczaski, E | 1 |
| Ball, H | 1 |
| Lu, W | 1 |
| Hanson, KH | 1 |
| Crowley, J | 1 |
| Salmon, SE | 1 |
| Keppen, M | 1 |
| Braun, TJ | 1 |
| Bonnet, JD | 1 |
| Scheithauer, W | 1 |
| Dittrich, C | 1 |
| Kornek, G | 1 |
| Haider, K | 1 |
| Linkesch, W | 1 |
| Gisslinger, H | 1 |
| Depisch, D | 1 |
| Williams, SF | 1 |
| Smiddy, J | 1 |
| Muto, T | 1 |
| Ebisawa, I | 1 |
| Mitsui, G | 1 |
| Rusanov, AM | 1 |
| Novoselova, GS | 1 |
| Smirnova, GA | 1 |
6 trials available for adenine and Leukocytopenia
| Article | Year |
|---|---|
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Topics: Acetylation; Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Femal | 1995 |
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
Topics: Acetylation; Adenine; Aging; Female; Humans; Imides; Isoquinolines; Leukocyte Count; Leukopenia; Mal | 1994 |
A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imides; Isoquinoline | 1998 |
[Clinical investigation on treatment of integrated traditional and Western medicine in hyperthyroidism with leukocytopenia induced by sulfourea drugs].
Topics: Adenine; Adolescent; Adult; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Hypert | 1998 |
Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Drug Resistance; Female; Granulocytes | 1991 |
Phase II study of amonafide in advanced breast cancer.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cardiomyopathies; Drug Evaluation; Fe | 1991 |
7 other studies available for adenine and Leukocytopenia
| Article | Year |
|---|---|
[Clinical experiences with adociron in the treatment of radioleukopenia in carcinoma of the cervix].
Topics: Adenine; Carcinoma; Female; Humans; Leukocyte Disorders; Leukopenia; Radiation Injuries; Radiotherap | 1962 |
[The effects of adenine on the leukopenia after x-irradiation. I].
Topics: Adenine; Humans; Leukocyte Disorders; Leukopenia; Radiation Effects; X-Rays | 1962 |
Treatment of peripheral leukopenia after cadaveric kidney transplantation.
Topics: Adenine; Adult; Azathioprine; Blood Transfusion; Cadaver; Drug Therapy, Combination; Female; Glycery | 1996 |
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Topics: Acetylation; Adenine; Adult; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Im | 1996 |
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Topics: Acetylation; Adenine; Antineoplastic Agents; Body Weight; Female; Humans; Imides; Isoquinolines; Leu | 1991 |
Malaria in Laos. II. Peripheral leucocyte counts during long-term administration of combined folic inhibitors (pyrimethamine with sulformethoxine or sulfamonomethoxine).
Topics: Adenine; Administration, Oral; Aniline Compounds; Asian People; Drug Combinations; Folic Acid Antago | 1971 |
[Treatment of experimental radiation leukopenia with Etaden].
Topics: Adenine; Animals; Leukopenia; Mice; Radiation Injuries, Experimental; Radiation-Protective Agents; R | 1967 |